Seven European big pharma drugmakers are to pool their research efforts with academic scientists and smaller companies in a new 196 million euros ($265 million) project designed to find tomorrow's medicines. Read the full story
Seven European big pharma drugmakers are to pool their research efforts with academic scientists and smaller companies in a new 196 million euros ($265 million) project designed to find tomorrow's medicines. Read the full story
Recordati announces successful pharma partnering alliance, concluding the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the United States of America, from Lundbeck, a big pharma company. Read the full story
H. Lundbeck A/S (LUN), the Nordic region’s second-largest drugmaker, failed to win recommendation from the European Union’s drug regulator for a treatment for Alzheimer’s disease, and is now seeking pharma partners to help develop the treatment Read the full story
H. Lundbeck, a top 50 pharma company has entered in a pharma partnering pact with ImaginAB to develop biologics for treatment of nervous system ailments. Read the full story
H. Lundbeck A/S (LUN), the Nordic region’s second-largest drugmaker, is in talks with several potential pharma partners to help develop a treatment for Alzheimer’s disease, Chief Executive Officer Ulf Wiinberg said.
This report provides all the information you require to better understand Lundbeck and its partnering interests and activities over the past seven years. Read the full story
Lundbeck, a big pharma company announced a pharma partners research collaboration with CHDI Foundation to investigate a targeted therapy for Huntington’s disease(HD) Read the full story
Genmab announced it had reached the second pre-clinical milestone in the collaboration with H. Lundbeck, triggering a €1 million payment. Read the full story
Oak Pharmaceuticals has acquired three off-patent, branded, hospital-based injectables from the US subsidiary of H. Lundbeck. Read the full story
In one of the largest partnering deals of the year, Lundbeck and Otsuka have entered into a long-term agreement for the development and commercialization of up to five innovative psychiatric and neuroscience products worldwide Read the full story